On August 7, 2025, NeOnc Technologies Holdings, Inc. announced it received $2.5 million in NIH STTR Grants to advance its research on NEO212 for treating gliomas and leukemia. Additionally, on August 11, 2025, they officially incorporated NuroMENA Holdings Ltd.